Arbor Trust Wealth Advisors LLC Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Arbor Trust Wealth Advisors LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 27.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,347 shares of the company's stock after selling 2,347 shares during the quarter. Arbor Trust Wealth Advisors LLC's holdings in Johnson & Johnson were worth $918,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Summit Wealth Partners LLC lifted its holdings in Johnson & Johnson by 0.6% during the second quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock valued at $1,463,000 after purchasing an additional 61 shares in the last quarter. Powers Advisory Group LLC lifted its stake in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock valued at $1,538,000 after buying an additional 61 shares in the last quarter. Eagle Wealth Strategies LLC boosted its holdings in Johnson & Johnson by 2.8% in the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock worth $372,000 after buying an additional 63 shares during the period. Knuff & Co LLC raised its holdings in Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock valued at $1,534,000 after acquiring an additional 64 shares during the period. Finally, Perkins Coie Trust Co lifted its position in shares of Johnson & Johnson by 1.8% in the third quarter. Perkins Coie Trust Co now owns 3,705 shares of the company's stock valued at $600,000 after acquiring an additional 65 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a report on Wednesday, November 6th. Citigroup cut their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 16th. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $173.27.

Johnson & Johnson Trading Up 0.7 %

Shares of NYSE:JNJ traded up $1.07 on Tuesday, hitting $148.10. 11,094,063 shares of the company's stock were exchanged, compared to its average volume of 8,798,511. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The business's 50 day simple moving average is $148.35 and its two-hundred day simple moving average is $156.11. The stock has a market capitalization of $356.57 billion, a price-to-earnings ratio of 21.43, a price-to-earnings-growth ratio of 2.39 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is presently 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company's stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.